Willingness to Receive COVID-19 Vaccination among Older Adults in Saudi Arabia: A Community-Based Survey

Mohammed Khaled Al-Hanawi 1,2,* , Noor Alshareef 1,2 and Rehab H. El-Sokkary 3

Citation: Al-Hanawi, M.K.; Alshareef, N.; El-Sokkary, R.H. Willingness to Receive COVID-19 Vaccination among Older Adults in Saudi Arabia: A Community-Based Survey. Vaccines 2021, 9, 1257. https://doi.org/10.3390/vaccines9111257

Abstract: Identifying the factors driving vaccine hesitancy can improve vaccine attitudes and motivate individuals to have the recommended vaccinations. However, failure to address the issue directly, or worse, ignoring it, could deepen such concerns, resulting in lower vaccination rates, leading to elevated rates of illness and vaccine-preventable deaths among older adults. The aim of this study was to explore the rate of acceptance of the COVID-19 vaccine among older adults in Saudi Arabia, along with the associated predicting factors and reasons for hesitancy. This study extracted data from a cross-sectional online survey on the acceptability of COVID-19 vaccination in Saudi Arabia, which was conducted from 8 to 14 December 2020. The sample of the study included 488 older adults aged 50 and older. The major data analytic tools employed in the study were bivariate and multivariable regression analyses. Among the 488 participants, 214 (43.85%) reported willingness to accept the COVID-19 vaccine when available. Older men were more likely to be willing to be vaccinated (adjusted odds ratio (aOR): 2.277; 95% confidence interval (CI): 1.092–4.745) than older women. High levels of education were significantly associated with willingness to be vaccinated. Older adults who had previously refused any vaccine were less likely to take the COVID-19 vaccine (aOR: 0.358; 95% CI: 0.154–0.830). Those who expressed a high or very high level of concern related to becoming infected were more likely to accept the vaccine against COVID-19 (aOR: 4.437; 95% CI: 2.148–9.168). Adverse side effects (27.01%), and safety and efficacy concerns (22.63%) were the most commonly cited reasons for vaccine hesitancy. The vaccination acceptance rate among older adults in Saudi Arabia is low. Interventions designed specifically for older adults addressing worries and concerns related to the vaccine are of paramount importance. In particular, these interventions should be tailored to address gender-based and health literacy level differences.

Keywords: COVID-19; older adults; hesitancy; Saudi Arabia; vaccine

1. Introduction

Many COVID-19 vaccine candidates have been identified as being suitable for emergency use [1]. However, maximizing the adoption of new vaccines that have been created at an extraordinary pace in comparison to past vaccine development timeframes is a serious issue that should be addressed. Vaccine hesitancy is defined as the “delay in acceptance or refusal of vaccination despite the availability of vaccination services” [2]. The World Health Organization (WHO) declared vaccine hesitancy as one of the top 10 global health threats in 2019 [3], as they referred to the rise in anti-vaccination myths by individuals and bots actively spreading fake news, especially on social media [4]. This pre-existing issue was accentuated during the COVID-19 pandemic, and thus poses a barrier to public acceptance of the COVID-19 vaccine, in addition to its overall impact on vaccination reluctance [5].

Since December 2020, COVID-19 vaccines have been introduced across the Kingdom of Saudi Arabia (KSA) in an effort to contain the transmission of the virus [6]. Since then,
the focus has shifted to determining the sufficient proportion of the general public that will be willing to be vaccinated and how to ensure they are adequately informed about the vaccine [7]. Vaccination has a direct impact on reducing infection, and vaccination against infectious disease has an indirect impact on herd immunity [8]. In a survey of 2137 Saudi adults, only 48% reported an intention to be vaccinated [9]. Results from a nationally representative study suggest that hesitation and refusal of the vaccine against COVID-19 will hinder the potential to reach herd immunity through immunization [10]. Understanding COVID-19 vaccine acceptance drivers is a global concern, as a lag in vaccination may lead to the rise and spread of variants that can overcome immunity conferred by prior disease and vaccination.

Many factors significantly influence the decision to be vaccinated, including individual risk perception, attitudes, self-efficacy, norms and traditions, barriers, and motivators, as well as social and cultural values [11]. Vaccine uptake among older adults is of particular importance. Due to decreased immunity (immunosenesence) and the high likelihood of existing chronic conditions, older adults are at a greater risk of developing severe illnesses and experiencing potentially serious complications [12–14]. Several studies have reported age as a significant risk factor for COVID-19 mortality [15,16]. Age also impacts viral clearance and the duration between hospitalization and death [17,18].

Initially, given the limited availability of the COVID-19 vaccine, expert committees were investigating strategic prioritization plans. Older adults and individuals with co-morbidities were designated to be in the first-tier group for vaccine roll-out [19] according to the policy of the Ministry of Health and the Saudi Centre of Disease Prevention and Control. The first phase targeted adults aged above 65 years and the second phase involved adults over 50 years old [6]. This population differs from the general population in a variety of ways, including information processing, risk perception, decision quality, and media consumption [20]. The aim of this study was to investigate the rate of acceptance of the COVID-19 vaccine among older adults (aged 50 and above), identify factors associated with the acceptance of the COVID-19 vaccination, and explore the reasons for hesitancy. Identifying these factors is critical to informing the design of future interventions aimed at maximizing vaccination uptake and effective messaging among this vulnerable group, and to devising effective strategies to support the success of the country’s public health policies.

2. Materials and Methods

2.1. Study Design and Sample

Data were extracted from an online cross-sectional survey designed to assess the willingness to accept a COVID-19 vaccine in the KSA that was administered from 8 to 14 December 2020 [9,21]. The self-reported questionnaire was designed and developed based on similar studies to assess vaccine acceptance for newly emerging infectious diseases [2,22–24]. The questionnaire was initially designed in English and was then translated into Arabic. The Arabic text was used to administer the study. The questionnaire consisted of three main parts. The first part of the questionnaire focused on the respondents' sociodemographic characteristics. The second part of the questionnaire focused on the respondents’ health status, immunization history, and fear of contracting COVID-19. The third part of the questionnaire focused on the respondent’s willingness to take a COVID-19 vaccine once available.

A simplified-snowball sampling technique was used for recruitment in which participants were asked to send on the invitations to their contacts. The online approach was used to generate valid samples in similar studies conducted in several countries including Saudi Arabia [24–27]. The survey link included detailed information about the aims and objectives of the study, and the potential to withdraw at any point, along with an assurance of anonymity and confidentiality of the data. Participants were also advised that their participation is voluntary. All adults (≥18 years) living in the KSA were eligible to participate. Once they had provided online informed consent, the participant was directed to the
Vaccines 2021, 9, 1257

A total of 2137 adults completed the survey out of 2319 originally participated, with a response rate of about 92%. A comprehensive description about the sampling method and data can be found elsewhere [9,21,28]. This study restricted analysis to older adults aged 50 and older, so the main analysis of this study is based on a sample of 488 older adults.

2.2. Variables

The main outcome for this study was the acceptance of COVID-19 vaccination among older adults (aged 50 and older). The following statement was provided: “scientists around the world are currently working on a vaccine that could prevent people from being infected with COVID-19. It is hoped that the vaccine will become available in a few months, and the respondents indicated their willingness to receive a COVID-19 vaccine under the scenario that one would become available “in the next few months, with an effective rate of the COVID-19 vaccine of 90–95%, provided free by the government”.

To assess the factors that may contribute to vaccine acceptance, information was collected on sociodemographic characteristics: age, gender, marital status, education level, employment status, and income level. Age was stratified as a categorical variable in two groups: 50–59 (the reference category) and ≥60 years. Gender and marital status were also coded as a binary variable (1 = male, 0 = female; 1 = married, 0 = unmarried, including single, widowed, and divorced). Educational attainment was assessed as high school level or below (reference), university degree, and postgraduate degree. Employment categories included government (reference group), private sector, retired, and unemployed. Monthly income (in Saudi Riyal (SR), 1 SR = 0.27 USD) was selected among the following categories: <3000 (reference), 3000–4999, 5000–6999, 7000–9999, 10,000–14,999, 15,000–19,999, 20,000–29,999, and ≥30,000.

Health status was assessed according to the presence or absence of a chronic illness (which has been associated with increased risk of exposure and/or severe COVID-19), prior vaccinated for seasonal influenza, and history of refusal for a physician-recommended vaccine. Psychological factors focused on the degree of perceived risk of COVID-19 infection, scored on a five-point Likert scale (1 = “very low”; 5 = “very high”). This section also assessed the respondents’ personal experience with COVID-19, including family members or friends with current or prior COVID-19 infection, and if any family or friends died from complications associated with COVID-19. Finally, the respondents were asked whether they agree with a mandatory COVID-19 vaccination policy in Saudi Arabia.

2.3. Statistical Analyses

The association of categorical variables with the dependent variable (willingness to accept the COVID-19 vaccine) was assessed using bivariate analysis with chi-squared tests. Multivariable logistic regression analysis was used to determine independent predictors of the dependent variable according to the adjusted odds ratio (aOR) and 95% confidence interval (CI). STATA 16.1 (StataCorp LP, College Station, TX, USA) was used for all analyses.

3. Results

Among the 488 participants aged 50 and older, 214 (43.85%) stated a willingness to accept a free COVID-19 vaccine when available. Table 1 presents the participant characteristics and assessed factors that potentially influence vaccination acceptance among older adults. Among the total participants, 212 (43.44%) were aged ≥60 years, 303 (62.09%) were male, 437 (89.55%) were married, 208 (42.62%) had a university degree, around one quarter (26.23%) were employed in the government sector, and 89 (18.24%) had a monthly income ≥30,000 SR.
Table 1. Frequency distribution and chi-squared analysis of intentions of COVID-19 vaccination among the older adults ($n = 488$).

| Variable                      | No Intention to Receive COVID-19 Vaccine ($n = 274$) | Intention to Receive COVID-19 Vaccine ($n = 214$) | Total ($n = 488$) | $p$-Value |
|-------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------|-----------|
| | $n$ | % | $n$ | % | $n$ | % |
| Age (years)                  |                                                 |                                                 |                    |           |
| 50 to 59                      | 156 | 56.93 | 120 | 56.07 | 276 | 56.56 | 0.849 |
| ≥60                           | 118 | 43.07 | 94  | 43.93 | 212 | 43.44 |           |
| Gender                       |                                                 |                                                 |                    |           |
| Female                        | 119 | 43.43 | 66  | 30.48 | 185 | 37.91 | <0.001 *** |
| Male                          | 155 | 56.57 | 148 | 69.16 | 303 | 62.09 |           |
| Marital Status                |                                                 |                                                 |                    |           |
| Unmarried                     | 31  | 11.31 | 20  | 9.35  | 51  | 10.45 | 0.481 |
| Married                       | 243 | 88.69 | 194 | 90.65 | 437 | 89.55 |           |
| Educational attainment        |                                                 |                                                 |                    |           |
| High school or below          | 71  | 25.91 | 51  | 23.83 | 122 | 25.00 | 0.646 |
| University degree             | 119 | 43.43 | 89  | 41.59 | 208 | 42.62 |           |
| Postgraduate degree           | 84  | 30.66 | 74  | 34.58 | 158 | 32.38 |           |
| Employment status             |                                                 |                                                 |                    |           |
| Government employee           | 65  | 23.72 | 63  | 29.44 | 128 | 26.23 | 0.270 |
| Private sector employee       | 39  | 14.23 | 20  | 9.35  | 59  | 12.09 |           |
| Unemployed                    | 36  | 13.14 | 29  | 13.55 | 65  | 13.32 |           |
| Retired                       | 134 | 48.91 | 102 | 47.66 | 236 | 48.36 |           |
| Monthly Income (in SR)        |                                                 |                                                 |                    |           |
| <3000                         | 16  | 5.84  | 12  | 5.61  | 28  | 5.74  | 0.582 |
| 3000–4999                     | 9   | 3.28  | 14  | 6.54  | 23  | 4.71  |           |
| 5000–6999                     | 16  | 5.84  | 10  | 4.6   | 26  | 5.33  |           |
| 7000–9999                     | 26  | 9.49  | 19  | 8.88  | 45  | 9.22  |           |
| 10,000–14,999                 | 56  | 20.44 | 37  | 17.29 | 93  | 19.06 |           |
| 15,000–19,999                 | 60  | 21.90 | 44  | 20.56 | 104 | 21.31 |           |
| 20,000–29,999                 | 47  | 17.15 | 33  | 15.42 | 80  | 16.39 |           |
| ≥30,000                       | 44  | 16.06 | 45  | 21.03 | 89  | 18.24 |           |
| Health status                 |                                                 |                                                 |                    |           |
| No chronic disease            | 145 | 52.92 | 86  | 40.19 | 231 | 47.34 | <0.001 *** |
| Chronic disease diagnosis     | 129 | 47.08 | 128 | 59.81 | 257 | 52.66 |           |
| Vaccination history           |                                                 |                                                 |                    |           |
| Never received flu vaccine    | 158 | 57.66 | 75  | 35.05 | 233 | 47.75 | <0.001 *** |
| Have received flu vaccine     | 116 | 42.34 | 139 | 64.95 | 255 | 52.25 |           |
| Vaccine willingness history   |                                                 |                                                 |                    |           |
| Never refused recommended vaccine | 210     | 76.64 | 200 | 93.46 | 410 | 84.02 | <0.001 *** |
| Have refused recommended vaccine | 64      | 23.36 | 14  | 6.54  | 78  | 15.98 |           |
| Family member tested positive for COVID-19 |                   |                                                 |                    |           |
| No                            | 161 | 58.76 | 140 | 65.42 | 301 | 61.68 | 0.133 |
| Yes                           | 113 | 41.24 | 74  | 34.58 | 187 | 38.32 |           |
Table 1. Cont.

| Variable | No Intention to Receive COVID-19 Vaccine (n = 274) | Intention to Receive COVID-19 Vaccine (n = 214) | Total (n = 488) | p-Value |
|----------|-----------------------------------------------|-----------------------------------------------|-----------------|---------|
| Friend tested positive for COVID-19 | | | | |
| No | 24 | 8.76 | 22 | 10.28 | 46 | 9.43 | 0.568 |
| Yes | 250 | 91.24 | 192 | 89.72 | 422 | 90.57 |
| Death of friend/family from COVID-19 | | | | |
| No | 181 | 66.06 | 134 | 62.62 | 315 | 64.55 | 0.430 |
| Yes | 93 | 33.94 | 80 | 37.38 | 173 | 35.45 |
| Perceived risk of becoming infected with COVID-19 | | | | |
| Low or very low | 136 | 49.64 | 51 | 23.83 | 187 | 38.32 | <0.001 *** |
| Fair | 79 | 28.83 | 90 | 42.06 | 169 | 34.63 |
| High or very high | 59 | 21.53 | 73 | 34.11 | 132 | 27.05 |
| Support mandatory COVID-19 vaccination in Saudi Arabia | | | | |
| No | 268 | 97.81 | 78 | 36.45 | 346 | 70.90 | <0.001 *** |
| Yes | 6 | 2.19 | 136 | 63.55 | 142 | 29.10 |

*** p < 0.01.

Table 1 also shows that among the 488 participants, 257 (52.66%) suffered from chronic illness, 255 (52.25%) received the flu vaccine in the past, while 78 (15.98%) refused taking vaccination in the past. Among the participants, 38.32% and 90.57% of their relatives and friends, respectively, were infected by COVID-19. However, 173 (35.45%) participants reported death of a family member or friend from COVID-19. Approximately one-quarter (27.05%) of the respondents were highly concerned about becoming infected with COVID-19 and 29.10% of the participants believed that the vaccine should be mandatory in the KSA. As shown in Table 1, gender, suffering from chronic diseases, history of flu vaccination, history of vaccine refusal, concern about COVID-19 infection, and believing in mandatory vaccination were all significant factors affecting willingness to vaccinate at the 1% level.

Table 2 presents the logistic regression estimates of factors associated with acceptance of a COVID-19 vaccine among older adults in the KSA. Men were more willing to accept vaccination (aOR: 2.277; 95% CI: 1.092–4.745) than women. Moreover, high education levels were associated with greater willingness to be vaccinated, as opposed to those with low level of education. Older adults who had refused vaccination in the past were less likely to be willing to be vaccinated (aOR: 0.358; 95% CI: 0.154–0.830) than those who had not refused vaccination in the past. Those who reported concerns about becoming infected with COVID-19 at a high or very high level were more likely to be willing to be vaccinated (aOR: 4.437; 95% CI: 2.148–9.168) compared with those who had a low or very low level of concerns of becoming infected. Regarding sociodemographic factors, marital status, employment status, and income level had no significant influence on the acceptability of COVID-19 vaccination among older adults in the KSA.
Table 2. Logistic regression estimates of factors associated with acceptance of COVID-19 vaccination among the older adults (n = 488).

| Variable                          | aOR  | 95% CI       | p-Value |
|----------------------------------|------|--------------|---------|
| **Age (years)**                  |      |              |         |
| 50 to 59 (ref)                   |      |              |         |
| ≥60                              | 1.258| 0.688–2.300  | 0.456   |
| **Gender**                       |      |              |         |
| Female (ref)                     |      |              |         |
| Male                             | 2.277| 1.092–4.745  | 0.028 **|
| **Marital Status**               |      |              |         |
| Unmarried (ref)                  |      |              |         |
| Married                          | 0.632| 0.260–1.535  | 0.311   |
| **Educational attainment**       |      |              |         |
| High school or below (ref)       |      |              |         |
| University degree                | 1.896| 0.880–4.084  | 0.090 * |
| Postgraduate degree              | 3.040| 1.270–7.277  | 0.013 **|
| **Employment status**            |      |              |         |
| Government employee (ref)        |      |              |         |
| Private sector employee          | 0.449| 0.165–1.226  | 0.118   |
| Unemployed                       | 2.397| 0.793–7.242  | 0.121   |
| Retired                          | 0.957| 0.457–2.004  | 0.908   |
| **Monthly Income (in SR)**       |      |              |         |
| <3000                            |      |              |         |
| 3000–4999                        | 2.728| 0.395–18.856 | 0.309   |
| 5000–6999                        | 1.963| 0.307–12.565 | 0.477   |
| 7000–9999                        | 3.169| 0.604–16.619 | 0.172   |
| 10,000–14,999                    | 1.736| 0.350–8.623  | 0.500   |
| 15,000–19,999                    | 1.582| 0.316–7.914  | 0.577   |
| 20,000–29,999                    | 1.285| 0.248–6.668  | 0.765   |
| ≥30,000                          | 2.560| 0.502–13.052 | 0.258   |
| **Health status**                |      |              |         |
| No chronic disease               |      |              |         |
| Chronic disease diagnosis        | 1.169| 0.668–2.044  | 0.585   |
| **Vaccination history**          |      |              |         |
| Never received flu vaccine       |      |              |         |
| Have received flu vaccine        | 1.661| 0.959–2.878  | 0.070 * |
| **Vaccine willingness history**  |      |              |         |
| Never refused recommended vaccine|      |              |         |
| Have refused recommended vaccine | 0.358| 0.154–0.830  | 0.017 **|
| **Family member tested positive for COVID-19** |      |              |         |
| No (ref)                         |      |              |         |
| Yes                              | 1.098| 0.612–1.969  | 0.755   |
| **Friend tested positive for COVID-19** |      |              |         |
| No (ref)                         |      |              |         |
| Yes                              | 1.132| 0.406–3.158  | 0.812   |
| **Death of friend/family from COVID-19** |      |              |         |
| No (ref)                         |      |              |         |
| Yes                              | 1.035| 0.589–1.818  | 0.905   |
Table 2. Cont.

| Variable                                      | aOR  | 95% CI          | p-Value |
|-----------------------------------------------|------|-----------------|---------|
| **Perceived risk of becoming infected with COVID-19** |      |                 |         |
| Low or very low (ref)                         | 1    |                 |         |
| Fair                                          | 3.473| 1.780–6.777     | <0.001 *** |
| High or very high                             | 4.437| 2.148–9.168     | <0.001 *** |
| **Support mandatory COVID-19 vaccination in Saudi Arabia** |      |                 |         |
| No (ref)                                      | 1    |                 |         |
| Yes                                           | 101.761| 39.173–264.348 | <0.001 *** |

*** p < 0.01, ** p < 0.05, * p < 0.1.

4. Discussion

We further investigated the reasons contributing to a lack of willingness to be vaccinated against COVID-19. As shown in Table 3, among the reasons put forward, approximately one-quarter (27.01%) of the respondents indicated that the primary reason for vaccine hesitancy was fear of adverse side effects. This was followed by safety and efficacy concerns (22.63%). The least frequent reason given was the lack of belief of COVID-19 in general (0.36%).

Table 3. Reasons for vaccine hesitancy among older adults.

| Reason                                              | n  | %   |
|-----------------------------------------------------|----|-----|
| Fear of adverse side effects                        | 74 | 27.01 |
| Safety and efficacy concerns                        | 62 | 22.63 |
| The speed of making the vaccine                     | 11 | 4.01 |
| The short duration of clinical trials               | 29 | 10.58 |
| Personal desire not to be vaccinated                | 20 | 7.30 |
| 1 think the vaccine is a plot                       | 31 | 11.31 |
| I do not believe in the existence of COVID-19        | 1  | 0.36 |
| I feel that masks and sanitizers are sufficient for protection | 23 | 8.39 |
| Other                                               | 23 | 8.39 |
| **Total**                                           | 274| 100 |

This study complements the emerging picture of COVID-19 vaccine acceptability by focusing on older adults in the KSA. The study puts forth several important key findings to public health authorities engaged in designing vaccine rollout programs or public health communication. The results reveal that the vaccination acceptance rate among the older population in Saudi Arabia reaches 44%. Receiving flu vaccination in the past, high level of risk perception, and believing that COVID-19 vaccination should be mandatory, as well as higher education levels, were found to be predictors of willingness to accept a COVID-19 vaccine. The findings obtained among older adults in this study resemble the findings obtained from a similar study conducted across the general population [9]. Being male, receiving flu vaccination, refusing vaccination in the past, concerns about contracting COVID-19, and believing that COVID-19 vaccination should be mandatory were found to be predictors of willingness to accept COVID-19 vaccine among both older adults and the general population.

Over half of the older adults (56.14%) reported that they are not willing to be vaccinated against COVID-19. In a previous study on the acceptability of a potential COVID-19 vaccine among the general public in Saudi Arabia, only 21% reported a lack of willingness to accept vaccination [29]. In the United States, vaccination hesitancy rates in October 2020 were approximately 50% for participants aged ≥50 years and 36.2% for older adults aged ≥60 years. In March 2021, the rates for the same categories fell to 39% and 21%, respectively [30]. The high refusal rate observed in this study could be partly due to the
rise of rumors and conspiracy theories about the safety and effectiveness of the vaccine. Such information has the potential to create fear, seed cynicism and doubts over the novel vaccine, consequently threatening public vaccine uptake [31].

The results of this study also offer insights into the individual characteristics that are likely associated with acceptability of the COVID-19 vaccine. Consistent with previous studies, we found that older male participants were more likely to accept vaccination than older female participants [32,33]. This could be explained by gender-based differences in adverse reactions and the humoral immune response following vaccination among women, and greater risks for COVID-19 complications, death, and infectivity among men [34–36]. Communication strategies geared at women might therefore be helpful in reducing general reluctance. Moreover, in line with previous studies, we found that vaccine acceptance is higher among highly educated people [37]. Lower educational attainment is linked to lower health literacy, thereby potentially resulting in misinterpretation of COVID-19 vaccination messages [38]. Thus, our findings underline the importance of developing tailored educational campaigns and communication messages that accommodate the differences in health literacy levels among older adults and that are delivered by trusted messengers.

Concerns surrounding the acceptability of a COVID-19 vaccine highlight important aspects for potential educational programs targeted at enhancing vaccination coverage. Major reasons for vaccine refusal among older adults in this study were related to “fear of severe side effects” as well as “safety and efficacy concerns”, which is consistent with prior studies [39–41]. In a recent analysis examining 13 studies surrounding vaccine hesitancy, many expressed concerns related to an unknown safety profile [42]. The fear of adverse effects expressed by respondents in this study may reflect the rapid speed of vaccine development and the scarce knowledge about the potential safety of the vaccine at the time of data collection [43]. This suggests that proactive messaging, initiated prior to a large-scale vaccination campaign roll-out, should emphasize the high efficacy rates of COVID-19 vaccines in reducing or eliminating disease, hospitalizations, and death, as well as communicate accurate information about potential side effects, including the rarity of severe adverse events that may have contributed to hesitancy [44,45].

One of the strongest correlates of COVID-19 vaccine acceptability in this study was the participants’ risk perception. Older adults with very high or high risk perceptions were more willing to accept the COVID-19 vaccine. These results coincide with the outcome of earlier studies showing correlations between perceived risk of infection and acceptability of the COVID-19 vaccine [24]. Participants in this study who believed that the COVID-19 vaccine should be made mandatory were more likely to be willing to accept vaccination for COVID-19. Although mandatory vaccination was not ruled out in Saudi Arabia at the time of data collection, mandatory vaccination can be warranted when confidence in safety and effectiveness is high, the expected utility of compulsory vaccination is higher than the alternatives, costs or penalties for non-compliance are proportionate, and if the threat to public health is critical [46]. Furthermore, in line with previous studies across different countries [40,47,48] and diseases [49,50], the results of this study show that previous vaccination behavior is a strong predictor of vaccine acceptability. Concerns related to the need for further information about the safety and utility of the vaccine have been reported to be a key reason for past vaccine refusal [40]. Moreover, previous studies have shown that vaccine acceptance is an individual habit that might apply to different diseases sharing the same mode of transmission and clinical characteristics [51,52].

This study is not without limitations. Although a high number of older adults use online applications and communication channels, the online nature of this survey may have limited the access to a larger number of potential participants. Moreover, participants were recruited by convenience sampling; thus, caution should be taken when applying the results of this study to other settings or populations. Furthermore, the self-administered questionnaire may be subject to social desirability. A further limitation is the cross-sectional
design of this study and the lack of available data on non-responders. Finally, the online survey used in this study could have impacted the generalizability of our results.

5. Conclusions

This study offers insight into the emerging global picture of the acceptability of the COVID-19 vaccine by primarily focusing on older adults in the KSA. Given the low level of vaccination acceptance among older adults, continuous encouragement to accept the COVID-19 vaccine among the vulnerable could result in reduced morbidity and mortality. Attention and efforts considering gender-based and educational attainment differences are needed in promoting vaccine acceptability. Effective communication of information that emphasizes the safety and efficacy aspects of these novel vaccines is necessary in order for vaccination to be successful among the older population.

Author Contributions: Conceptualization: M.K.A.-H.; data curation: M.K.A.-H.; formal analysis: M.K.A.-H.; methodology: M.K.A.-H.; project administration: M.K.A.-H.; software: M.K.A.-H.; supervision: M.K.A.-H.; validation: M.K.A.-H., N.A. and R.H.E.-S.; funding acquisition: M.K.A.-H.; writing—original draft preparation, M.K.A.-H., N.A. and R.H.E.-S.; writing—review and editing, M.K.A.-H., N.A. and R.H.E.-S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Institutional Fund Projects under grant number IFPRC-207-121-2020. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement: All procedures performed in this study involving human participants complied with the institutional and/or national research committee ethical standards and the 1964 Helsinki Declaration and subsequent amendments or equivalent ethical standards. This research has been reviewed and given a favorable opinion by King Abdulaziz University. The study was designed and conducted according to the ethical principles established by King Abdulaziz University. Therefore, ethical approval was obtained from the Biomedical Ethics Research Committee, Faculty of Medicine, King Abdulaziz University (Ref-628-20).

Informed Consent Statement: Online informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets generated and/or analyzed during the current study are not publicly available due to privacy and confidentiality agreements as well as other restrictions but are available from the corresponding author on reasonable request.

Acknowledgments: This research was funded by the Institutional Fund Projects under grant number IFPRC-207-121-2020. Therefore, authors gratefully acknowledge technical and financial support from the Ministry of Education and King Abdulaziz University, Jeddah, Saudi Arabia.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. FDA. US Food & Drug Administration: COVID-19 Vaccines. Available online: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines (accessed on 9 August 2021).
2. MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [CrossRef] [PubMed]
3. WHO. Ten Health Issues WHO Will Tackle This Year. Available online: https://www.who.int/vietnam/news/feature-stories/detail/ten-threats-to-global-health-in-2019 (accessed on 1 August 2021).
4. Johnson, N.F.; Velásquez, N.; Restrepo, N.J.; Leahy, R.; Gabriel, N.; El Oud, S.; Zheng, M.; Manrique, P.; Wuchty, S.; Lupu, Y. The online competition between pro-and anti-vaccination views. Nature 2020, 582, 230–233. [CrossRef] [PubMed]
5. Roozenbeek, J.; Schneider, C.R.; Dryhurst, S.; Kerr, J.; Freeman, A.L.; Recchia, G.; Van Der Bles, A.M.; Van Der Linden, S. Susceptibility to misinformation about COVID-19 around the world. R. Soc. Open Sci. 2020, 7, 201199. [CrossRef] [PubMed]
6. MOH. COVID-19 Vaccines. Available online: https://covid19awareness.sa/en/archives/10691 (accessed on 2 August 2021).
7. Bloom, B.R.; Nowak, G.J.; Orenstein, W. “When will we have a vaccine?”—Understanding questions and answers about Covid-19 vaccination. N. Engl. J. Med. 2020, 383, 2202–2204. [CrossRef]
8. Betsch, C.; Böhm, R.; Korn, L. Inviting free-riders or appealing to prosocial behavior? game-theoretical reflections on communicating herd immunity in vaccine advocacy. Health Psychol. 2013, 32, 978. [CrossRef]
9. Alfageeh, E.I.; Alshareef, N.; Angawi, K.; Alhazmi, F.; Chirwa, G.C. Acceptability of a COVID-19 vaccine among the Saudi population. *Vaccines* 2021, 9, 226. [CrossRef]

10. Paul, E.; Steptoe, A.; Fancourt, D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. *Lancet Reg. Health-Eur.* 2021, 1, 100012. [CrossRef]

11. Betsch, C.; Böhm, R.; Chapman, G.B. Using behavioral insights to increase vaccination policy effectiveness. *Policy Insights Behav. Brain Sci.* 2015, 2, 61–73. [CrossRef]

12. Kang, S.-J.; Jung, S.I. Age-related morbidity and mortality among patients with COVID-19. *Infect. Chemother.* 2020, 52, 154. [CrossRef]

13. McElhanney, J.E.; Verschoor, C.; Pawelec, G. Zoster Vaccination in Older Adults: Efficacy and Public Health Implications. *J. Gerontol. Ser. A* 2019, 74, 1239–1243. [CrossRef]

14. Krueger, P.; St Amant, O.; Loeb, M. Predictors of Pneumococcal Vaccination among Older Adults with Pneumonia: Findings from the Community Acquired Pneumonia Impact Study. *BMC Geriatr.* 2010, 10, 1–9. [CrossRef] [PubMed]

15. Leung, C. Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China. *Mech. Ageing Dev.* 2020, 188, 112155. [CrossRef] [PubMed]

16. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020, 395, 1045–1062. [CrossRef]

17. Hu, X.; Xing, Y.; Jia, J.; Ni, W.; Liang, J.; Zhao, D.; Song, X.; Gao, R.; Jiang, F. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. *Sci. Total Environ.* 2020, 728, 138812. [CrossRef]

18. Leung, C. Clinical features of deaths in the novel coronavirus epidemic in China. *Rev. Med. Virol.* 2020, 30, e2103. [CrossRef]

19. Cox, L.S.; Bellantuono, I.; Lord, J.M.; Sapey, E.; Mannick, J.B.; Partridge, L.; Gordon, A.L.; Steves, C.J.; Witham, M.D. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. *Lancet Healthy Longev.* 2020, 1, e55–e57. [CrossRef]

20. Betsch, C.; Rossmann, C.; Pletz, M.W.; Vollmar, H.C.; Freytag, A.; Wichmann, O.; Hanke, R.; Hanke, W.; Heinemeier, D.; Schmid, P. Increasing influenza and pneumococcal vaccine uptake in the elderly: Study protocol for the multi-methods prospective intervention study Vaccination 60+. *BMC Public Health* 2018, 18, 1–13. [CrossRef]

21. Quttan, A.; Alshareef, N.; Alsharqi, O.; Al Rahahleh, N.; Chirwa, G.C.; Al-Hanawi, M.K. Acceptability of a COVID-19 vaccine among healthcare workers in the Kingdom of Saudi Arabia. *Front. Med.* 2021, 8, 83. [CrossRef]

22. Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. *Vaccines* 2020, 8, 482. [CrossRef]

23. Quinn, S.C.; Jamison, A.M.; An, J.; Hancock, G.R.; Freimuth, V.S. Measuring vaccine hesitancy, confidence, trust and flu vaccine uptake: Results of a national survey of White and African American adults. *Vaccine* 2019, 37, 1168–1173. [CrossRef] [PubMed]

24. Sherman, S.M.; Smith, L.E.; Sim, J.; Amlôt, R.; Cutts, M.; Dasch, H.; Rubin, G.J.; Sevdalis, N. COVID-19 vaccination intention in the UK: Results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. *Hum. Vaccines Immunother.* 2021, 17, 1612–1621. [CrossRef]

25. Al-Hanawi, M.K.; Angawi, K.; Alshareef, N.; Quttan, A.; Helmy, H.Z.; Abudawood, Y.; Alqurashi, M.; Kattan, W.M.; Kadasah, N.A.; Chirwa, G.C. Knowledge, attitude and practice toward COVID-19 among the public in the Kingdom of Saudi Arabia: A cross-sectional study. *Front. Public Health* 2020, 8, 217. [CrossRef] [PubMed]

26. Harapan, H.; Wagner, A.L.; Yufika, A.; Winardi, W.; Anwar, S.; Gan, A.K.; Setiawan, A.M.; Rajamooorthy, Y.; Sofyan, H.; Mudatsir, M. Acceptance of a COVID-19 vaccine in Southeast Asia: A cross-sectional study in Indonesia. *Front. Public Health* 2020, 8, 381. [CrossRef]

27. Al-Qerem, W.A.; Jarab, A.S. COVID-19 vaccination acceptance and its associated factors among a Middle Eastern population. *Front. Public Health* 2021, 9, 34. [CrossRef]

28. Al-Hanawi, M.K.; Ahmad, K.; Haque, R.; Keramat, S.A. Willingness to receive COVID-19 vaccination among adults with chronic diseases in the Kingdom of Saudi Arabia. *J. Infect. Public Health* 2021, 14, 1489–1496. [CrossRef]

29. Al-Mohaithef, M.; Padhi, B.K. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: A web-based national survey. *J. Multidiscip. Healthc.* 2020, 13, 1657. [CrossRef]

30. Daly, M.; Jones, A.; Robinson, E. Public Trust and Willingness to Vaccinate against COVID-19 in the US from October 14, 2020, to March 29, 2021. *JAMA* 2021, 325, 2397–2399. [CrossRef]

31. Loomba, S.; de Figueiredo, A.; Piatak, S.J.; de Graaf, K.; Larson, H.J. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. *Nat. Hum. Behav.* 2021, 5, 337–348. [CrossRef] [PubMed]

32. Nikolovski, J.; Koldijk, M.; Weverling, G.J.; Spertus, J.; Sperling, J.; Turakhia, M.; Saxon, L.; Gibson, M.; Whang, J.; Sarich, T.; Zambon, R. Factors indicating intention to vaccinate with a COVID-19 vaccine among older US Adults. *PLoS ONE* 2021, 16, e0251963. [CrossRef] [PubMed]

33. Sallam, M.; Dababseh, D.; Eid, H.; Al-Mahzoum, K.; Al-Haidar, A.; Taim, D.; Yaseen, A.; Ababneh, N.A.; Bakri, F.G.; Mahafzah, A. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. *Vaccines* 2021, 9, 42. [CrossRef]

34. Poland, G.A.; Ovsyannikova, I.G.; Jacobson, R.M. Adverse reactions: The emerging field of vaccine adverse event immunogenetics. *Pediatric Infect. Dis. J.* 2009, 28, 431. [CrossRef] [PubMed]
35. Galbadage, T.; Peterson, B.M.; Awada, J.; Buck, A.S.; Ramirez, D.A.; Wilson, J.; Gunasekera, R.S. Systematic review and meta-analysis of sex-specific COVID-19 clinical outcomes. *Front. Med.* 2020, 7, 348. [CrossRef]
36. Klein, S.L.; Jedlicka, A.; Pekosz, A. The Xs and Y of immune responses to viral vaccines. *Lancet Infect. Dis.* 2010, 10, 338–349. [CrossRef]
37. Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of US adults. *Ann. Intern. Med.* 2020, 173, 964–973. [CrossRef]
38. Clouston, S.A.; Manganello, J.A.; Richards, M. A life course approach to health literacy: The role of gender, educational attainment and lifetime cognitive capability. *Age Ageing* 2017, 46, 493–499. [CrossRef] [PubMed]
39. Almaghaslah, D.; Alsayari, A.; Kandasamy, G.; Vasudevan, R. COVID-19 Vaccine Hesitancy among Young Adults in Saudi Arabia: A Cross-Sectional Web-Based Study. *Vaccines* 2021, 9, 330. [CrossRef]
40. Reno, C.; Maietti, E.; Fantini, M.P.; Savoia, E.; Manzoli, L.; Montalti, M.; Gori, D. Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy. *Vaccines* 2021, 9, 378. [CrossRef]
41. Malani, P.N.; Solway, E.; Kullgren, J.T. Older Adults’ Perspectives on a COVID-19 Vaccine. In *JAMA Health Forum*; American Medical Association: Chicago, IL, USA, 2020; p. e201539.
42. Solís Arce, J.S.; Warren, S.S.; Meriggi, N.F.; Scacco, A.; McMurry, N.; Voors, M.; Syunyaev, G.; Malik, A.A.; Aboutajdine, S.; Adeojo, O. COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. *Nat. Med.* 2021. [CrossRef]
43. Callaway, E. Russia’s fast-track coronavirus vaccine draws outrage over safety. *Nature* 2020, 584, 334–335. [CrossRef]
44. Goldstein, S.; MacDonald, N.E.; Guirguis, S. Health communication and vaccine hesitancy. *Vaccine* 2015, 33, 4212–4214. [CrossRef] [PubMed]
45. Puri, N.; Coomes, E.A.; Haghbayan, H.; Gunaratne, K. Social media and vaccine hesitancy: New updates for the era of COVID-19 and globalized infectious diseases. *Hum. Vaccines Immunother.* 2020, 16, 2586–2593. [CrossRef] [PubMed]
46. Savulescu, J. Good reasons to vaccinate: Mandatory or payment for risk? *J. Med. Ethics* 2021, 47, 78–85. [CrossRef]
47. Caserotti, M.; Girardi, P.; Rubaltelli, E.; Tasso, A.; Lotto, L.; Gavazzi, L. Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents. *Soc. Sci. Med.* 2021, 272, 113688. [CrossRef] [PubMed]
48. Ruiz, J.B.; Bell, R.A. Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey. *Vaccine* 2021, 39, 1080–1086. [CrossRef] [PubMed]
49. Liao, Q.; Cowling, B.J.; Lam, W.W.T.; Fielding, R. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: A longitudinal study. *PLoS ONE* 2011, 6, e17713. [CrossRef]
50. Chor, J.S.; Nga, K.L.; Goggins, W.B.; Wong, M.C.; Wong, S.Y.; Lee, N.; Leung, T.Y.; Rainer, T.H.; Griffiths, S.; Chan, P.K. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: Two questionnaire surveys. *BMJ* 2009, 339, b3391. [CrossRef]
51. Lin, C.J.; Nowalk, M.P.; Toback, S.L.; Rousculp, M.D.; Raymund, M.; Ambrose, C.S.; Zimmerman, R.K. Importance of vaccination habit and vaccine choice on influenza vaccination among healthy working adults. *Vaccine* 2010, 28, 7706–7712. [CrossRef]
52. Wang, K.; Wong, E.L.Y.; Ho, K.F.; Cheung, A.W.L.; Chan, E.Y.Y.; Yeoh, E.K.; Wong, S.Y.S. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey. *Vaccine* 2020, 38, 7049–7056. [CrossRef]